STOCK TITAN

BeiGene Ltd - BGNE STOCK NEWS

Welcome to our dedicated news page for BeiGene (Ticker: BGNE), a resource for investors and traders seeking the latest updates and insights on BeiGene.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BeiGene's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BeiGene's position in the market.

Rhea-AI Summary
BeiGene, Ltd. reported a strong first quarter with product revenue of $410.3 million, a 56.9% increase compared to the prior-year period. BRUKINSA® and tislelizumab showed significant global growth. BRUKINSA's global sales reached $211.4 million, more than doubling from the first quarter of 2022. Tislelizumab sales in China reached $114.9 million, a 31% increase from the prior-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.44%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.44%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
none
BeiGene Ltd

Nasdaq:BGNE

BGNE Rankings

BGNE Stock Data

17.13B
761.00M
19.85%
48.17%
1.85%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
China (Mainland)
Changping District

About BGNE

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.